1st Alpine Winter Conference

Confirmed Speakers


Keynote Speakers

 Erick M. CARREIRA
Erick M. CARREIRA
ETH ZÜRICH, Zürich, Switzerland

KL01 - Recent Developments in Strategies and Tactics Towards the Synthesis of Complex Secondary Metabolites as Enabling Tools for the Study of Biology and Medicine

 Benjamin CRAVATT
Benjamin CRAVATT
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States
Read more

KL02 - Activity-based proteomics – Protein and Ligand Discovery on a Global Scale

 Anabella VILLALOBOS
Anabella VILLALOBOS
BIOGEN, Cambridge, United States
Read more

KL03 - Novel Approaches in the Design of CNS Drug Candidates and PET Ligands

Addressing Preclinical Toxicity – Approaches and Lessons Learned

 Andreas BRINK
Andreas BRINK
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

PL06 - Reducing Bioactivation Potential of Drug Candidates: Implications for Preclinical Drug Optimization

 Peter DRAGOVICH
Peter DRAGOVICH
GENENTECH INC., San Francisco, United States
Read more

PL04 - Mechanism-Based Toxicities Associated With NAMPT Inhibition and Related Mitigation Strategies

 Martin PETTERSSON
Martin PETTERSSON
PFIZER, Cambridge, United States
Read more

OC02 - Small Structural Changes Leading to Major Impact on Safety: Developing Safety Strategies in Medicinal Chemistry

 Douglas THOMSON
Douglas THOMSON
CELLZOME GMBH, Heidelberg, Germany
Read more

PL05 - Utilizing in Depth Understanding of a Molecules Off-Target Profile to Tailor Clinical and Preclinical Safety Assessments

Advances in Lead Generation

 Monika ERMANN
Monika ERMANN
EVOTEC LTD, Oxfordshire, United Kingdom
Read more

PL08 - A Chemist’s Guide to Modern Phenotypic Drug Discovery

 Koen HEKKING
Koen HEKKING
MERCACHEM-SYNCOM, Nijmegen, The Netherlands
Read more

OC03 - CDK8 Inhibitors with Pre-Engineerd Long Residence Time, Exhibiting Efficacy in Tumor Xenograft Models

 Eva Maria MARTIN
Eva Maria MARTIN
ELI LILLY, Madrid, Spain
Read more

PL07 - ADAS (Affinity Directed Automated Synthesis): A New Technology to Accelerate Lead Generation

 Sanne SCHRODER GLAD
Sanne SCHRODER GLAD
NUEVOLUTION A/S, Copenhagen, Denmark
Read more

PL09 - From Multiple Hit Series to (Pre)Clinical Candidates Using DNA-Encoded Library Technology

Advances in Synthetic Methods

 Varinder K. AGGARWAL
Varinder K. AGGARWAL
UNIVERSITY OF BRISTOL, Bristol, United Kingdom
Read more

PL01 - Assembly Line Synthesis

 Thorsten BACH
Thorsten BACH
TECHNISCHE UNIVERSITÄT MÜNCHEN, Garching, Germany
Read more

PL02 - Photochemical Reactions en route to Structurally Complex Molecules

 Paolo MELCHIORRE
Paolo MELCHIORRE
INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA (ICIQ), Tarragona, Spain

PL03 - Expanding the Potential of Organocatalysis with Light

 Peter O'BRIEN
Peter O'BRIEN
UNIVERSITY OF YORK, York, United Kingdom
Read more

OC01 - Exploring 3-D Pharmaceutical Space: New CH Functionalisation Reactions of Oxygen and Sulfur Heterocycles

Alternative Modalities

 Niall ANDERSON
Niall ANDERSON
GLAXOSMITHKLINE, Hertfordshire, United Kingdom
Read more

OC05 - Proteolysis Targetting Chimera: A New Frontier in Medicinal Chemistry

 Kerry BENENATO
Kerry BENENATO
MODERNA THERAPEUTICS, Cambridge, United States

PL13 - Messenger RNA as a Novel Therapeutic Approach

 David TELLERS
David TELLERS
MERCK & CO. INC (MSD), West Point, United States
Read more

PL11 - Intracellular Delivery of Macromolecules

 Eric VALEUR
Eric VALEUR
ASTRAZENECA, Västra Frölunda, Sweden
Read more

PL12 - New Modalities Probe and Hit Finding for Challenging Targets in Cardiovascular and Metabolic Diseases

Challenges and Opportunities in Fragment Based Drug Discovery

 Christoph GAUL
Christoph GAUL
NOVARTIS, Basel, Switzerland

OC07 - Fragment-Centric Methodologies for the Discovery of DOT1L Inhibitors

 Jean-François GUICHOU
Jean-François GUICHOU
CBS INSERM U1054, Montpellier, France

OC12 - Rational Design of Small-Molecules Inhibitors of Human Cyclophilins with a Pan Viral Activities by Fragment Based Drug Design Using a Linking Strategy

 Tom HEIGHTMAN
Tom HEIGHTMAN
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom

PL17 - Drug Discovery for Challenging Targets by X-ray Crystallographic Fragment Screening

 Rod HUBBARD
Rod HUBBARD
UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom
Read more

PL18 - The Impact of Fragments on Drug Discovery

Chemical Biology in Drug and Target Discovery

 Gonçalo BERNARDES
Gonçalo BERNARDES
INSTITUTO DE MEDICINA MOLECULAR, LISBON, PORTUGAL & UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Read more

OC04 - Chemical Physiology of Antibody Conjugates and Natural Products

 Kai JOHNSSON
Kai JOHNSSON
MAX-PLANCK INSTITUTE FOR MEDICAL RESEARCH, Heidelberg, Germany
Read more

PL10 - Fluorescent and Bioluminescent Sensor Proteins

Late Stage Functionalization

 Nicolai CRAMER
Nicolai CRAMER
ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE, Lausanne, Switzerland
Read more

PL15 - The Quest for Efficient Ligands in Asymmetric C-H Functionalizations

 Darren J. DIXON
Darren J. DIXON
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

PL16 - Catalytic Approaches to Simplifying Synthesis

 Matthew GAUNT
Matthew GAUNT
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom

Read more

PL14 - New Chemical Tools for the Late Stage Functionalization of Biomolecules

 Mark LAUTENS
Mark LAUTENS
UNIVERSITY OF TORONTO, Toronto, ON, Canada

Read more

OC06 - Synthetic Routes to Oxindoles via Metal Catalysis

Drug Discovery Tales

 Mike HANN
Mike HANN
GLAXOSMITHKLINE, Stevenage, United Kingdom
Read more

OC10 - Molecular Accessibility - Measuring and Understanding the Intracellular Free Concentration of Drugs During Lead Optimisation

 Holger MONENSCHEIN
Holger MONENSCHEIN
TAKEDA CALIFORNIA, INC, San Diego, United States
Read more

OC09 - Discovery of Tak-041: A Potent and Selective Gpr139 Agonist for the Treatment of Negative Symptoms Associated with Schizophrenia

 Jean QUANCARD
Jean QUANCARD
NOVARTIS, Basel, Switzerland
Read more

OC08 - Discovery of Allosteric Malt1 Protease Inhibitors with High in Vivo Efficacy

 Brian RAYMER
Brian RAYMER
PFIZER, Cambridge, United States
Read more

OC11 - Discovery of a Ketohexokinase Inhibitor for the Treatment of Nafld/Nash: Fragment-to-Candidate via Structure-Based Drug Design and Parallel Chemistry


EFMC Sponsored Event

Silver Sponsor

Bronze Sponsors

Sponsors

Media Partner

Copyright 2018 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys